Vascular anomalies refer to a broad spectrum of abnormalities that involve blood vessels. It includes vascular malformations and proliferating vascular tumors. The development of innovative medications like propranolol for infantile hemangiomas and advancements in sclerotherapy agents are significantly contributing to the pipeline expansion for vascular anomalies drugs. Moreover, robust support from regulatory bodies is anticipated to encourage further investments in novel treatments for this condition.
Report Coverage
The Vascular Anomalies Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into vascular anomalies therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Vascular Anomalies. The vascular anomalies report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The vascular anomalies pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with vascular anomalies treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to vascular anomalies.
Vascular Anomalies Drug Pipeline Outlook
Vascular anomalies are a group of disorders or abnormalities of the vascular system, affecting blood vessels, lymph vessels, or both. This condition can occur as a result of abnormal development of the blood vessels, leading to localized defects such as birthmarks or growths that can be disfiguring. The symptoms vary depending on the type of malformation. Vascular anomalies can cause functional or cosmetic problems. It can occur in any part of the body but is usually found in the head and neck.
Vascular anomalies therapeutics include low molecular weight heparin that can help in treating pain or preventing blood clots. Sclerotherapy is also used for shrinking the malformation or closing off abnormal veins. Additionally, advancements in imaging technologies such as MRI, CT scans, and ultrasound, along with adherence to vascular anomalies treatment guidelines, are expected to support the pipeline growth in the coming years.
Vascular Anomalies Epidemiology
Vascular anomalies are a relatively common disorder of the endothelium, affecting arteries, veins, capillaries, or lymphatics. The prevalence of vascular anomalies is estimated to be around 5% . The condition is classified into tumors or malformations. According to a review article published in Circulation Research (2021), vascular malformations are reported to affect approximately 1% to 1.5% of the population.
Vascular Anomalies – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of vascular anomalies drug candidates based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
EMR’s pipeline assessment report covers 50+ drug analyses based on drug classes:
- Recombinant Fusion Proteins
- Small Molecule
- Monoclonal Antibody
- Peptide
- Polymer
- Gene Therapy
EMR’s vascular anomalies report assessment covers 50+ drug analyses based on the route of administration.
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials, with a substantial number of vascular anomalies emerging drugs undergoing clinical development.
Vascular Anomalies – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under vascular anomalies pipeline analysis include recombinant fusion proteins, small molecule, monoclonal antibody, peptide, polymer, and gene therapy. The vascular anomalies report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for vascular anomalies.
Vascular Anomalies Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the vascular anomalies drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed vascular anomalies therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in vascular anomalies clinical trials:
- Palvella Therapeutics, Inc.
- Novartis Pharmaceuticals
- Protara Therapeutics
- Inozyme Pharma
- Vascular Therapies, Inc.
- Vaderis Therapeutics AG
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for vascular anomalies. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of vascular anomalies drug candidates.
Drug: Sirolimus
The objective of this multicenter clinical trial is to investigate the efficacy and safety of the vascular anomalies drug candidate Sirolimus in patients who are refractory to standard care. The study is under Phase III clinical development and has an estimated 250 participants.
Drug: Alpelisib
Sponsored by Novartis Pharmaceuticals, this Phase II/III multi-center trial aims to examine the efficacy of Alpelisib in the treatment of lymphatic malformations associated with a PIK3CA mutation in pediatric and adult patients. The interventional study has enrolled about 230 subjects and is expected to be completed by May 2030.
Reasons To Buy This Report
The Vascular Anomalies Drug Report provides a strategic overview of the latest and future landscape of treatments for vascular anomalies. it provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within vascular anomalies pipeline insights.
Key Questions Answered in the Vascular Anomalies – Pipeline Insight Report
- Which companies/institutions are leading the vascular anomalies drug development?
- What is the efficacy and safety profile of vascular anomalies pipeline drugs?
- Which company is leading the vascular anomalies pipeline development activities?
- What is the current vascular anomalies commercial assessment?
- What are the opportunities and challenges present in the vascular anomalies drug pipeline landscape?
- What is the efficacy and safety profile of vascular anomalies pipeline drugs?
- Which company is conducting major trials for vascular anomalies drugs?
- Which companies/institutions are involved in vascular anomalies collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in vascular anomalies?
Vascular Malformations Market
Global Clinical Trials Market
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Vascular Anomalies
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Types of Vascular Anomalies
- 3.5 Diagnosis
- 3.6 Treatment
- 4 Patient Profile: Vascular Anomalies
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Vascular Anomalies: Epidemiology Snapshot
- 5.1 Vascular Anomalies Incidence by Key Markets
- 5.2 Vascular Anomalies – Patients Seeking Treatment in Key Markets
- 6 Vascular Anomalies: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Vascular Anomalies: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Vascular Anomalies, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Vascular Anomalies Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Vascular Anomalies Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Drug: Sirolimus
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Drug: Alpelisib
- 10.2.3 Drug: QTORIN 3.9% Rapamycin Anhydrous Gel
- 10.2.4 Other Drugs
- 11 Vascular Anomalies Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Drug: Alpelisib, Drug: Mirdametinib
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Biological: TARA-002
- 11.2.3 Other Drugs
- 12 Vascular Anomalies Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Drug 1
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Other Drugs
- 13 Vascular Anomalies Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug 1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 Vascular Anomalies, Key Drug Pipeline Companies
- 14.1 Palvella Therapeutics, Inc.
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Novartis Pharmaceuticals
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Protara Therapeutics
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Inozyme Pharma
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 Vascular Therapies, Inc.
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 Vaderis Therapeutics AG
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook